KeyBanc Believes Teladoc (NYSE: TDOC) Won’t Stop Here

By Ryan Adsit

In a report released today, Brent Bracelin from KeyBanc reiterated a Buy rating on Teladoc (NYSE: TDOC), with a price target of $37. The company’s shares closed on Friday at $35.95, close to its 52-week high of $37.55.

According to, Bracelin is a 5-star analyst with an average return of 12.0% and a 72.8% success rate. Bracelin covers the Technology sector, focusing on stocks such as Cornerstone Ondemand, Riverbed Technology, and Medidata Solutions.

Currently, the analyst consensus on Teladoc is Strong Buy and the average price target is $39.71, representing a 10.5% upside.

In a report issued on September 11, Piper Jaffray also reiterated a Buy rating on the stock with a $42 price target.

The company has a one year high of $37.55 and a one year low of $14. Currently, Teladoc has an average volume of 1.02M.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teladoc, Inc. engages in the provision of telehealth platform, delivering healthcare anytime, and anywhere via mobile devices, the internet, video, and phone. Its physicians treat a wide range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Dallas, TX.